Risuteganib-a novel integrin inhibitor for the treatment of non-exudative (dry) age-related macular degeneration and diabetic macular edema.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Risuteganib-a novel integrin inhibitor for the treatment of non-exudative (dry) age-related macular degeneration and diabetic macular edema.
- Published In:
- Expert opinion on investigational drugs, 29(6), 547-554 (2020)
- Authors:
- Shaw, Lincoln T, Mackin, Anna, Shah, Reanna, Jain, Siona, Jain, Prisha, Nayak, Ravi, Hariprasad, Seenu M
- Database ID:
- RPEP-05128
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-05128APA
Shaw, Lincoln T; Mackin, Anna; Shah, Reanna; Jain, Siona; Jain, Prisha; Nayak, Ravi; Hariprasad, Seenu M. (2020). Risuteganib-a novel integrin inhibitor for the treatment of non-exudative (dry) age-related macular degeneration and diabetic macular edema.. Expert opinion on investigational drugs, 29(6), 547-554. https://doi.org/10.1080/13543784.2020.1763953
MLA
Shaw, Lincoln T, et al. "Risuteganib-a novel integrin inhibitor for the treatment of non-exudative (dry) age-related macular degeneration and diabetic macular edema.." Expert opinion on investigational drugs, 2020. https://doi.org/10.1080/13543784.2020.1763953
RethinkPeptides
RethinkPeptides Research Database. "Risuteganib-a novel integrin inhibitor for the treatment of ..." RPEP-05128. Retrieved from https://rethinkpeptides.com/research/shaw-2020-risuteganiba-novel-integrin-inhibitor
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.